← Latest news 
Odyssey Therapeutics rallies in Nasdaq debut hitting nearly 900 million valuation after IPO beats targets
Business
Published on 8 May 2026
Investors bid up a biotech debut after it raised more than planned
Odyssey Therapeutics, an autoimmune disease-focused biotech, surged 11.1% in its Nasdaq debut to a $899.9 million valuation. The company raised $279 million in its IPO, surpassing its target, a result that points to renewed investor appetite for biotech listings. Founder Dr. Gary D. Glick’s track record adds extra confidence to the story.
- Odyssey Therapeutics opened up 11.1% on Nasdaq
- Valuation at debut landed near $899.9 million
- IPO proceeds totaled $279 million, above the target
- Strong debut suggests a revival in biotech IPO interest
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times